

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/507,925	. 07/05/2005	Jonathan B. Baell	18223	6810
Edward W. Gro	7590 01/10/2008		EXAM	INER
Edward W Grolz Scully Scott Murphy & Presser			CHANDRAKUMAR, NIZAL S	
400 Garden City Plaza Garden City, NY 11530		ART UNIT	PAPER NUMBER	
•	•		1625	
			MAIL DATE	DELIVERY MODE
		•	01/10/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/507,925	BAELL ET AL.	
Office Action Summary	Examiner	Art Unit	
	Nizal S. Chandrakumar	1625	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.11 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period v - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. ED (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on 2a) ☐ This action is FINAL . 2b) ☑ This 3) ☐ Since this application is in condition for alloware closed in accordance with the practice under Expression in the practice of the practice of the practice.	action is non-final. nce except for formal matters, pro		
Disposition of Claims			
4) ☐ Claim(s) 1-21 is/are pending in the application. 4a) Of the above claim(s) 21 is/are withdrawn f 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-20 are subject to restriction and/or expressions.	rom consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Settion is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	4) ☐ Interview Summary Paper No(s)/Mail D 5) ☐ Notice of Informal F	ate	
Paper No(s)/Mail Date	6) Other:		

DETAILED ACTION

This application filed 07/05/2005 is a 371 of PCT/AU03/00351 03/20/2003.

Claims 1-21 are before the Examiner and subject to the following Election/Restrictions.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group 1, claim(s) 1-17, 20, drawn to compounds of formula I, wherein A=B=furan, and the linker is -O-CH2-C6H4-CH2-O-, and the linker and the benzofuran oxygen have meta relationship.

Group 2, claim(s) 1-17, 20, drawn to compounds of formula I, wherein A=B=furan, and the linker is -O-(CH2)n-O-, and the linker and the benzofuran oxygen have meta relationship.

Group 3, claim(s) 1-17, 20, drawn to compounds of formula I, wherein A=B=furan, and the linker is -S-(CH2)n-S-, and the linker and the benzofuran oxygen have meta relationship.

Group 4, claim(s) 1-17; 20, drawn to compounds of formula I, wherein A=B=furan, and the linker is -N-(CH2)n-N-, and the linker and the benzofuran oxygen have meta relationship.

Group 5, claim(s) 1-17, 20, drawn to compounds of formula I, wherein A=B=furan, and the linker is -O-CH2-HET-CH2-O- wherein HET is furan, thiophene, thiadiazole, pyridine, pyrimidine, pyrazine, or pyridazine, , further the linker and the benzofuran oxygen have meta relationship.

Application/Control Number:

10/507,925 Art Unit: 1625

Group 6, claim(s) 1-17, 20, drawn to compounds of formula I, wherein A=B=furan, and the linker is other than ones indicated in Groups 1-5, , and the linker and the benzofuran oxygen have meta relationship. Election of species is required.

Group 7, claim(s) 1-17, 20, drawn to compounds of formula I, wherein A and B are not furan, and the linker is other than ones indicated in Groups 1-5. Election of species is required.

Group 8, claim(s) 1-17, 20, drawn to compounds of formula I, not included in Groups 1-7. Election of species is required.

Group 9, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 1. Group 10, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 2. Group 11, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 3. Group 12, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 4. Group 13, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 5. Group 14, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 6. Group 15, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 7. Group 16, claim(s) 18, 19 are drawn to method of treating various diseases using compound of Group 8. The term 'use of in claim 21 is non-statutory claim language. Therefore claim 21 is withdrawn from further consideration.

The inventions listed as Groups 1-16 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The non-variable element present in all these group is also present in commercially available well-known Khellinone and thus the subject matter is not a contribution over the prior art.

Application/Control Number:

10/507,925

Art Unit: 1625

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction were not required; because the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nizal S. Chandrakumar whose telephone number is 571-272-6202. The examiner can normally be reached on 8.30 am - 5 pm Monday- Friday.

10/507,925

Art Unit: 1625

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached at 571-272-0867 or Primary Examiner D. Margaret Seaman can be reached at 571-272-0694. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nizal S. Chandrakumar

MARGARET SEAMAN PRIMARY EXAMINER